ABROCITINIB TREATMENT IN ADOLESCENTS AND ADULTS WITH MODERATE-TO-SEVERE ATOPIC DERMATITIS: EARLY PRURITUS RESPONSES FROM PHASE 3 TRIALS JADE MONO-1 AND JADE MONO-2

被引：0

作者：

Stander, Sonja ^{[1
]}

Yosipovitch, Gil ^{[2
]}

Silverberg, Jonathan I. ^{[3
]}

Simpson, Eric L. ^{[4
]}

Sinclair, Rodney ^{[5
]}

Su, John C. ^{[6
,7
,8
]}

Kerkmann, Urs ^{[9
]}

Gallardo, William Romero ^{[10
]}

Valdez, Hernan ^{[11
]}

Rojo, Ricardo ^{[12
]}

Biswas, Pinaki ^{[13
]}

Farooqui, Saleem A. ^{[14
]}

机构：

[1] Munster Univ Hosp, Dept Dermatol, Ctr Chron Pruritus, Munster, Germany

[2] Univ Miami, Miller Sch Med, Miami Itch Ctr, Miami, FL USA

[3] George Washington Univ, Sch Med & Hlth Sci, Dept Dermatol, Washington, DC 20052 USA

[4] Oregon Hlth & Sci Univ, Dept Dermatol, Portland, OR 97201 USA

[5] Sinclair Dermatol, East Melbourne, Vic, Australia

[6] Univ Melbourne, Royal Childrens Hosp, Murdoch Childrens Res Inst, Dept Populat Allergy, Parkville, Vic, Australia

[7] Univ Melbourne, Royal Childrens Hosp, Murdoch Childrens Res Inst, Dept Dermatol, Parkville, Vic, Australia

[8] Univ Melbourne, Royal Childrens Hosp, Murdoch Childrens Res Inst, Dept Paediat, Parkville, Vic, Australia

[9] Pfizer Pharma GmbH, Global Med Affairs Inflammat & Immunol, Berlin, Germany

[10] Pfizer Ltd, Global Med Affairs Inflammat & Immunol, Surrey, England

[11] Pfizer Inc, Global Prod Dev Inflammat & Immunol, New York, NY USA

[12] Pfizer Inc, Global Prod Dev Inflammat & Immunol, Groton, CT USA

[13] Pfizer Inc, Biostat, New York, NY USA

[14] Pfizer Ltd, Clin Dev & Operat, Surrey, England

来源：

ACTA DERMATO-VENEREOLOGICA | 2021年 / 101卷

关键词：

D O I：

暂无

中图分类号：

R75 [皮肤病学与性病学];

学科分类号：

100206 ;

摘要：

PT13

引用

页码：56 / 56

页数：1

共 50 条

[1] ABROCITINIB TREATMENT IN ADOLESCENTS AND ADULTS WITH MODERATE-TO-SEVERE ATOPIC DERMATITIS: KEY EFFICACY AND SAFETY RESULTS FROM PHASE 3 TRIALS JADE MONO-1 AND JADE MONO-2
Simpson, Eric L.
Silverberg, Jonathan I.
Forman, Seth
Wollenberg, Andreas
Thyssen, Jacob P.
Flohr, Carsten
Feeney, Claire
Biswas, Pinaki
DiBonaventura, Marco
Cameron, Michael C.
Rojo, Ricardo
Valdez, Hernan
ACTA DERMATO-VENEREOLOGICA, 2021, 101 : 13 - 14
[2] Examining the relationships among abrocitinib monotherapy, pruritus severity and skin clearance in patients with moderate-to-severe atopic dermatitis: results from JADE MONO-1 and JADE MONO-2
Simpson, E. L.
Yosipovitch, G.
Staender, S.
Silverberg, J. I.
Thyssen, J. P.
Kwatra, S. G.
Luger, T.
Guttman-Yassky, E.
Tom, W. L.
Bushmakin, A. G.
Cappelleri, J. C.
Chan, G.
Feeney, C.
Yin, N.
Valdez, H.
DiBonaventura, M.
Myers, D. E.
BRITISH JOURNAL OF DERMATOLOGY, 2021, 184 (03) : E76 - E77
[3] Interpreting the relationship between pruritus and quality of life in patients with moderate-to-severe atopic dermatitis: a post-hoc analysis of JADE MONO-1 and JADE MONO-2
Gooderham, M. J.
Yosipovitch, G.
Stander, S.
Fonacier, L.
Szepietowski, J. C.
Deleuran, M.
Girolomoni, G.
Bushmakin, A. G.
Cappelleri, J. C.
Watkins, M.
Feeney, C.
Valdez, H.
Rojo, R.
DiBonaventura, M.
Myers, D. E.
BRITISH JOURNAL OF DERMATOLOGY, 2021, 185 (03) : E139 - E140
[4] ABROCITINIB TREATMENT IN ADOLESCENTS AND ADULTS WITH MODERATE-TO-SEVERE ATOPIC DERMATITIS: KEY EFFICACY RESULTS BY RACE AND REGION OF ENROLLMENT IN JADE MONO-2
Cho, Sang-Hyun
Sinclair, Rodney
Li, Hang
Fujita, Nobuhiro
Freeman, Michael
Kornmann, Oliver
Seo, Seong-Jun
Wang, Bo
Fujita, Kayo
Biswas, Pinaki
Valdez, Hernan
Tyring, Stephen K.
ACTA DERMATO-VENEREOLOGICA, 2021, 101 : 56 - 56
[5] Efficacy and safety of abrocitinib in patients with moderate-to-severe atopic dermatitis: results from the phase III JADE MONO-2 study
Silverberg, J.
Simpson, E. L.
Thyssen, J. P.
Gooderham, M.
Chan, G.
Feeney, C.
Biswas, P.
Valdez, H.
DiBonaventura, M.
Nduaka, C.
Rojo, R.
BRITISH JOURNAL OF DERMATOLOGY, 2020, 183 (04) : E100 - E100
[6] Efficacy and safety of abrocitinib in patients with moderate-to-severe atopic dermatitis: results from the phase III, JADE MONO-1 study
Simpson, E. L.
Sinclair, R.
Forman, S.
Wollenberg, A.
Asch, R.
Cork, M.
Bieber, T.
Thyssen, J. P.
Yosipovitch, G.
Magnolo, N.
Maari, C.
Flohr, C.
Feeney, C.
Biswas, P.
Tatulych, S.
Valdez, H.
Rojo, R.
BRITISH JOURNAL OF DERMATOLOGY, 2020, 183 (04) : E105 - E106
[7] Economic impact of abrocitinib monotherapy and combination therapy in patients with moderate-to-severe atopic dermatitis: results from JADE MONO-2 and JADE COMPARE
Gooderham, M. J.
Chu, C. -Y.
Rojo, R.
Valdez, H.
Biswas, P.
Cameron, M. C.
Feeney, C.
Encinas, G. A.
Peeples-Lamirande, K.
Cappelleri, J. C.
Myers, D. E.
DiBonaventura, M.
BRITISH JOURNAL OF DERMATOLOGY, 2021, 184 (03) : E72 - E72
[8] Pruritus, Sleep, and Productivity: A Post Hoc Analysis of Abrocitinib Versus Placebo in Patients With Moderate-to-Severe Atopic Dermatitis (AD) From JADE MONO-2
Yosipovitch, Gil
Fonacier, Luz
Stander, Sonja
Su, John
Gooderham, Melinda
Szepietowski, Jacek
Deleuran, Mette
Girolomoni, Giampiero
Biswas, Pinaki
Feeney, Claire
Valdez, Hernan
Rojo, Ricardo
Thorpe, Andrew
Chan, Gary
Cappelleri, Joseph
DiBonaventura, Marco
Myers, Daniela
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 2021, 147 (02) : AB34 - AB34
[9] Abrocitinib improves work productivity through improvement in pruritus and sleep: Results from the JADE MONO-2 study in patients with moderate-to-severe atopic dermatitis (AD)
Yosipovitch, Gil
Deleuran, Mette
Su, John
Fonacier, Luz
Bushmakin, Andrew G.
Cappelleri, Joseph C.
Feeney, Claire
Thorpe, Andrew
Rojo, Ricardo
Valdez, Hernan
Myers, Daniela E.
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2021, 85 (03) : AB153 - AB153
[10] Efficacy and safety of abrocitinib in adults and adolescents with moderate-to-severe atopic dermatitis (JADE MONO-1): a multicentre, double-blind, randomised, placebo-controlled, phase 3 trial
Simpson, Eric L.
Sinclair, Rodney
Forman, Seth
Wollenberg, Andreas
Aschoff, Roland
Cork, Michael
Bieber, Thomas
Thyssen, Jacob P.
Yosipovitch, Gil
Flohr, Carsten
Magnolo, Nina
Maari, Catherine
Feeney, Claire
Biswas, Pinaki
Tatulych, Svitlana
Valdez, Hernan
Rojo, Ricardo
LANCET, 2020, 396 (10246): : 255 - 266

← 1 2 3 4 5 →